LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Avalo Therapeutics

Suletud

14.6 -4.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.33

Max

15.47

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+138.71% upside

Avalo Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. nov 2025, 21:55 UTC

Tulu

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12. nov 2025, 21:34 UTC

Tulu

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12. nov 2025, 23:44 UTC

Market Talk

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12. nov 2025, 23:38 UTC

Market Talk

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12. nov 2025, 22:30 UTC

Market Talk
Tulu

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12. nov 2025, 22:18 UTC

Tulu

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12. nov 2025, 22:12 UTC

Market Talk

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12. nov 2025, 22:05 UTC

Tulu

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q Adj EPS 48c >PAAS

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q Rev $884.4M >PAAS

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q EPS 45c >PAAS

12. nov 2025, 22:03 UTC

Tulu

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q Net C$1.8B >MFC

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q EPS C$1.02 >MFC

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12. nov 2025, 21:52 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12. nov 2025, 21:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

12. nov 2025, 21:49 UTC

Tulu

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12. nov 2025, 21:48 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12. nov 2025, 21:40 UTC

Tulu

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Võrdlus sarnastega

Hinnamuutus

Avalo Therapeutics Prognoos

Hinnasiht

By TipRanks

138.71% tõus

12 kuu keskmine prognoos

Keskmine 37 USD  138.71%

Kõrge 48 USD

Madal 25 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Avalo Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat